Sutro Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary

• Sutro Biopharma Inc STRO.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -59 cents. The mean expectation of ten analysts for the quarter was for a loss of 40 cents per share. Wall Street expected results to range from -64 cents to -4 cents per share.

• Revenue rose 148% to $63.75 million from a year ago; analysts expected $14.25 million.

• Sutro Biopharma Inc's reported EPS for the quarter was a loss of 14 cents​.

• The company reported a quarterly loss of $11.5 million.

• Sutro Biopharma Inc shares had risen by 12.4% this quarter and lost 56.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 19.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell."

• Wall Street's median 12-month price target for Sutro Biopharma Inc is $2.00, about 61.4% above its last closing price of $0.77

This summary was machine generated from LSEG data August 12 at 12:01 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)